Organisation paid for research Program year 2025 Source: CMS Open Payments

St Jude Clinical Research LLC

Neither a doctor nor a teaching hospital

Research payments

$2,849,464

55 payments

Through program year 2025, St Jude Clinical Research LLC is reported as receiving $2,849,464 in research payments, across 55 payments.

By program year

3 rows
Year Kind Amount Payments
2025 Research $2,081,932 33
2024 Research $680,308 20
2023 Research $87,224 2

Breakdown

Who paid Research payments · program years 2023–2025
  1. Sanofi US Services Inc. $2,154,567 33 payments
  2. Pfizer Inc. $428,583 20 payments
  3. Amgen Inc. $266,314 2 payments
Studies the money was for Research payments · program years 2023–2025
  1. A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment $938,141 11 payments
  2. Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD $622,596 11 payments
  3. A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis $578,330 10 payments
  4. A Phase 2 Randomized Doubleblind Placebocontrolled Study to Investigate the Efficacy and Safety of Pf07275315 and Pf07264660 in Adult Participants With Moderatesevere Atopic Dermatitis $428,583 20 payments
  5. A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) $189,978 1 payment
  6. P3 AD Monotherapy Induction $76,336 1 payment
  7. A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) $15,500 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record